Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) have been assigned an average recommendation of "Moderate Buy" from the twelve analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $23.80.
Several brokerages have commented on IOVA. Wells Fargo & Company restated an "equal weight" rating and issued a $14.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, August 18th. Truist Financial lowered their price objective on shares of Iovance Biotherapeutics to $18.00 in a report on Tuesday, August 23rd. JMP Securities restated a "buy" rating and issued a $25.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, September 12th. Robert W. Baird decreased their target price on shares of Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating for the company in a research note on Friday, August 5th. Finally, Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $31.00 to $30.00 in a research note on Friday, August 5th.
Get Iovance Biotherapeutics alerts:Institutional Investors Weigh In On Iovance Biotherapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. Herold Advisors Inc. bought a new stake in shares of Iovance Biotherapeutics during the first quarter valued at approximately $33,000. Spire Wealth Management purchased a new stake in Iovance Biotherapeutics in the first quarter worth approximately $47,000. Lazard Asset Management LLC boosted its holdings in Iovance Biotherapeutics by 38.5% in the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 934 shares during the last quarter. Retirement Group LLC boosted its holdings in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Iovance Biotherapeutics by 1,459.9% in the second quarter. Nisa Investment Advisors LLC now owns 6,614 shares of the biotechnology company's stock worth $73,000 after purchasing an additional 6,190 shares during the last quarter.
Iovance Biotherapeutics Trading Up 0.5 %
Iovance Biotherapeutics stock opened at $9.58 on Friday. The firm has a 50-day moving average of $11.31 and a 200-day moving average of $12.59. The firm has a market cap of $1.51 billion, a P/E ratio of -4.01 and a beta of 0.50. Iovance Biotherapeutics has a 1-year low of $6.18 and a 1-year high of $27.96.Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the firm posted ($0.53) EPS. Research analysts forecast that Iovance Biotherapeutics will post -2.53 earnings per share for the current fiscal year.
Iovance Biotherapeutics Company Profile
(Get Rating)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Featured Articles
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.